Syncom Formulations (India) Limited
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- ₹8.05
- Today's High:
- ₹8.85
- Open Price:
- ₹8.85
- 52W Low:
- ₹4.55
- 52W High:
- ₹11.65
- Prev. Close:
- ₹8.73
- Volume:
- 1143371
Company Statistics
- Market Cap.:
- ₹975.82 million
- Book Value:
- 1.662
- Revenue TTM:
- ₹1.81 billion
- Operating Margin TTM:
- 7.17%
- Gross Profit TTM:
- ₹529.20 million
- Profit Margin:
- 7.88%
- Return on Assets TTM:
- 4.7%
- Return on Equity TTM:
- 0%
Company Profile
Syncom Formulations (India) Limited had its IPO on under the ticker symbol 524470.
The company operates in the Healthcare sector and Drug Manufacturers - Major industry. Syncom Formulations (India) Limited has a staff strength of 716 employees.
Stock update
Shares of Syncom Formulations (India) Limited opened at ₹8.85 at the start of the last trading session i.e. 2023-09-13.
The stocks traded within a range of ₹8.05 - ₹8.85, and closed at ₹8.35.
This is a -4.35% slip from the previous day's closing price.
A total volume of 1,143,371 shares were traded at the close of the day’s session.
In the last one week, shares of Syncom Formulations (India) Limited have slipped by -4.9%.
Syncom Formulations (India) Limited's Key Ratios
Syncom Formulations (India) Limited has a market cap of ₹975.82 million, indicating a price to book ratio of 0.9433 and a price to sales ratio of 0.783.
In the last 12-months Syncom Formulations (India) Limited’s revenue was ₹1.81 billion with a gross profit of ₹529.20 million and an EBITDA of ₹170.48 million. The EBITDA ratio measures Syncom Formulations (India) Limited's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Syncom Formulations (India) Limited’s operating margin was 7.17% while its return on assets stood at 4.7% with a return of equity of 0%.
In Q2, Syncom Formulations (India) Limited’s quarterly earnings growth was a positive 33.3% while revenue growth was a negative 45.7%.
Syncom Formulations (India) Limited’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 10.2345
- PEG
Its diluted EPS in the last 12-months stands at ₹0.184 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Syncom Formulations (India) Limited’s profitability.
Syncom Formulations (India) Limited stock is trading at a EV to sales ratio of 0.747 and a EV to EBITDA ratio of 6.043. Its price to sales ratio in the trailing 12-months stood at 0.783.
Syncom Formulations (India) Limited stock pays annual dividends of ₹0.02 per share, indicating a yield of 1.49% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- ₹3.78 billion
- Total Liabilities
- ₹1.13 billion
- Operating Cash Flow
- ₹-449527000.00
- Capital Expenditure
- ₹206.35 million
- Dividend Payout Ratio
- 0%
Syncom Formulations (India) Limited ended 2024 with ₹3.78 billion in total assets and ₹0 in total liabilities. Its intangible assets were valued at ₹3.78 billion while shareholder equity stood at ₹2.56 billion.
Syncom Formulations (India) Limited ended 2024 with ₹0 in deferred long-term liabilities, ₹1.13 billion in other current liabilities, 940000000.00 in common stock, ₹1.62 billion in retained earnings and ₹0 in goodwill. Its cash balance stood at ₹77.52 million and cash and short-term investments were ₹746.41 million. The company’s total short-term debt was ₹831,815,000 while long-term debt stood at ₹0.
Syncom Formulations (India) Limited’s total current assets stands at ₹1.82 billion while long-term investments were ₹0 and short-term investments were ₹660.09 million. Its net receivables were ₹755.07 million compared to accounts payable of ₹0 and inventory worth ₹212.00 million.
In 2024, Syncom Formulations (India) Limited's operating cash flow was ₹-449527000.00 while its capital expenditure stood at ₹206.35 million.
Comparatively, Syncom Formulations (India) Limited paid ₹0 in dividends in 2024.
Other key metrics
- Current Trading Price
- ₹8.35
- 52-Week High
- ₹11.65
- 52-Week Low
- ₹4.55
- Analyst Target Price
- ₹
Syncom Formulations (India) Limited stock is currently trading at ₹8.35 per share. It touched a 52-week high of ₹11.65 and a 52-week low of ₹11.65. Analysts tracking the stock have a 12-month average target price of ₹.
Its 50-day moving average was ₹8.2 and 200-day moving average was ₹7.45 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 4055.9% of the company’s stock are held by insiders while 0% are held by institutions.
Frequently Asked Questions About Syncom Formulations (India) Limited
Similar Industry Stocks (Drug Manufacturers - Major)
Most Active
Top Gainers
Top Losers
About
Syncom Formulations (India) Limited, a pharmaceutical company, discovers, develops, manufactures, and markets a range of healthcare products in India. The company offers approximately 300 pharmaceutical formulations in various dosage forms, such as tablets, capsules, liquids orals, liquid vials and ampoules injections, dry vial injections, dry syrups, ointments, inhalers, and herbals. Its products comprise generics, alpha adrenoceptor agonists, analgesics, antipyretics, anti-inflammatory, anti-ulcer agents, antibiotics, antidepressants, antifungals, antihistamines, antimalarial, antiplatelet agents, antiprotozoal, antivirals, bronchodilators, calcium antagonists, cardiac medicines, central nervous stimulants, cephelo sporins, cortico steroids, estrogen, cough suppressants, erectile dysfunction, and electrolite. The company also offers histamines, homeostatic, hypoglycemic, hypolipidaemics, local anesthetics, multivitamins and nutritional supplements, sedative anticonvulsants, stimulants, and sympathomimetic products, as well as products used in the treatment of gout. In addition, it exports active pharmaceutical ingredients and surgical products; agro and confectionary products comprising rice, wheat flour, chickpeas, soy doc, biscuits, and candies; and fasteners, steel bars, roofing sheets, and jute bags, as well as metal scrap. Additionally, the company rents properties. Syncom Formulations (India) Limited was founded in 1985 and is based in Indore, India.